Working… Menu

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04351243
Recruitment Status : Completed
First Posted : April 17, 2020
Last Update Posted : April 5, 2021
Roivant Sciences, Inc.
Information provided by (Responsible Party):
Kinevant Sciences GmbH

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 1, 2020
Actual Study Completion Date : April 1, 2021